NASDAQ:KZIA
Kazia Therapeutics Limited Stock Company Profile
$0.272
-0.0105 (-3.72%)
At Close: May 03, 2024
Information
Three International Towers, Level 24 300 Barangaroo Avenue
Sydney NSW 2000
www.kaziatherapeutics.com
Industry: Biotechnology
Sector: Healthcare
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
